Leanza Liu, MD
Endocrinology, Diabetes & Metabolism · North Chesterfield, VANPI 1215105135
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.0% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Novo Nordisk at 42.0% of the total. 2025 is the largest year on record at $300, 3.5 times the $85 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in VA, where the typical reported total is $1,187.
Across 90 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$584
- Lilly USA, LLC$208
- Abbott$125
- Medtronic$120
- Bayer$79
- Dexcom, Inc.$62
- plus $211 from 8 others
What the payments were for
- Food & beverage$1,27892%
- Education$312%
- Other$806%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $584 |
| Lilly USA, LLC | 13 | $208 |
| Abbott | 5 | $125 |
| Medtronic(2 entities) | 6 | $120 |
| Bayer | 4 | $79 |
| Dexcom, Inc. | 4 | $62 |
| Acella Pharmaceuticals, LLC | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Amgen | 2 | $32 |
| Chiesi USA, Inc. | 1 | $31 |
| AstraZeneca | 2 | $26 |
| Cequr Corporation | 1 | $20 |
| AbbVie | 1 | $14 |
| Pfizer | 1 | $13 |
How this compares
$1,389 in reported general payments places this provider in the 50th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 582 | $801,460 |
| JardianceEmpagliflozin | 593 | $517,265 |
| TrulicityDulaglutide | 150 | $197,289 |
| ProliaDenosumab | 53 | $93,429 |
| MounjaroTirzepatide | 58 | $81,626 |
| JanuviaSitagliptin Phosphate | 85 | $74,359 |
| FarxigaDapagliflozin Propanediol | 91 | $72,577 |
| TradjentaLinagliptin | 86 | $59,618 |
| FiaspInsulin Aspart (Niacinamide) | 34 | $40,009 |
| Humalog Kwikpen U-100Insulin Lispro | 169 | $32,639 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 54 | $27,180 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 273 | $25,289 |
| HumalogInsulin Lispro | 113 | $24,677 |
| NovologInsulin Aspart | 108 | $24,676 |
| Novolog FlexpenInsulin Aspart | 110 | $23,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $584 | $866,146724 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $208 | $306,887357 claims |
| AmgenProlia | $32 | $93,42953 claims |
| AstraZenecaFarxiga | $26 | $72,57791 claims |
| BayerKerendia | $79 | $12,79316 claims |
| AbbVieSynthroid | $14 | $3,74087 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $41 | $3,356104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in North Chesterfield
- James WigandNorth Chesterfield$9K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.